Foghorn Therapeutics Inc. (FHTX) financial statements (2022 and earlier)

Company profile

Business Address 500 TECHNOLOGY SQUARE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments101,13692,795
Cash and cash equivalents101,13692,795
Other undisclosed current assets358,42697,892
Total current assets:459,562190,687
Noncurrent Assets
Operating lease, right-of-use asset38,51642,804
Property, plant and equipment 19,528
Restricted cash and investments1,7331,733
Other noncurrent assets2,400842
Other undisclosed noncurrent assets17,563 
Total noncurrent assets:60,21264,907
TOTAL ASSETS:519,774255,594
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,38112,841
Accounts payable3,8193,680
Accrued liabilities9,5629,161
Deferred revenue28,3172,024
Other undisclosed current liabilities6,9943,981
Total current liabilities:48,69218,846
Noncurrent Liabilities
Long-term debt and lease obligation51,33878,015
Long-term debt, excluding current maturities 19,654
Operating lease, liability51,33858,361
Liabilities, other than long-term debt322,87312,546
Deferred revenue322,73012,546
Other liabilities143 
Total noncurrent liabilities:374,21190,561
Total liabilities:422,903109,407
Stockholders' equity
Stockholders' equity attributable to parent96,871146,187
Common stock44
Additional paid in capital361,133309,126
Accumulated other comprehensive loss(10)(7)
Accumulated deficit(264,256)(162,936)
Total stockholders' equity:96,871146,187
TOTAL LIABILITIES AND EQUITY:519,774255,594

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues2,500430
Sublease income2,500 
Gross profit:2,500430
Operating expenses(102,053)(68,961)
Other undisclosed operating loss(1,181) 
Operating loss:(100,734)(68,531)
Nonoperating expense(586)(269)
Interest and debt expense(1,233)(1,201)
Loss before gain (loss) on sale of properties:(102,553)(70,001)
Other undisclosed net income 1,201
Net loss:(102,553)(68,800)
Other undisclosed net income attributable to parent1,233 
Net loss available to common stockholders, diluted:(101,320)(68,800)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(102,553)(68,800)
Comprehensive loss:(102,553)(68,800)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,230(7)
Comprehensive loss, net of tax, attributable to parent:(101,323)(68,807)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: